- Home
- BTBD vs SBFM Comparison
BTBD vs SBFM Comparison
Compare BTBD & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- SBFM
- Stock Information
- Founded
- BTBD 1987
- SBFM 2006
- Country
- BTBD United States
- SBFM United States
- Employees
- BTBD N/A
- SBFM N/A
- Industry
- BTBD Restaurants
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- SBFM Health Care
- Exchange
- BTBD Nasdaq
- SBFM Nasdaq
- Market Cap
- BTBD 10.5M
- SBFM 3.7M
- IPO Year
- BTBD 2021
- SBFM N/A
- Fundamental
- Price
- BTBD $1.65
- SBFM $3.06
- Analyst Decision
- BTBD
- SBFM
- Analyst Count
- BTBD 0
- SBFM 0
- Target Price
- BTBD N/A
- SBFM N/A
- AVG Volume (30 Days)
- BTBD 6.8K
- SBFM 121.6K
- Earning Date
- BTBD 11-13-2024
- SBFM 11-11-2024
- Dividend Yield
- BTBD N/A
- SBFM N/A
- EPS Growth
- BTBD N/A
- SBFM N/A
- EPS
- BTBD N/A
- SBFM N/A
- Revenue
- BTBD $14,306,676.00
- SBFM $30,481,982.00
- Revenue This Year
- BTBD N/A
- SBFM $86.70
- Revenue Next Year
- BTBD N/A
- SBFM $126.76
- P/E Ratio
- BTBD N/A
- SBFM N/A
- Revenue Growth
- BTBD 1.65
- SBFM 109.82
- 52 Week Low
- BTBD $1.25
- SBFM $2.42
- 52 Week High
- BTBD $3.05
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- BTBD 52.23
- SBFM 49.32
- Support Level
- BTBD $1.60
- SBFM $2.85
- Resistance Level
- BTBD $1.85
- SBFM $3.05
- Average True Range (ATR)
- BTBD 0.10
- SBFM 0.15
- MACD
- BTBD -0.00
- SBFM 0.02
- Stochastic Oscillator
- BTBD 43.02
- SBFM 63.89
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.